(Q34135364)

31 July 2017

1 reference

title

Clinical pharmacokinetics of depot leuprorelin (English)

1 reference

31 July 2017

1 reference

1 reference

2

Teresita Mazzei

1 reference

31 July 2017

Piero Periti

1

1 reference

31 July 2017

Enrico Mini

series ordinal

3

1 reference

31 July 2017

publication date

1 January 2002

1 reference

Clinical Pharmacokinetics

31 July 2017

published in

1 reference

31 July 2017

volume

41

1 reference

31 July 2017

issue

7

1 reference

31 July 2017

page(s)

485-504

1 reference

https://scigraph.springernature.com/pub.10.2165/00003088-200241070-00003

31 July 2017

exact match

0 references

cites work

Vaginal absorption of a potent luteinizing hormone-releasing hormone analogue (leuprolide) in rats. IV: Evaluation of the vaginal absorption and gonadotropin responses by radioimmunoassay

1 reference

12 December 2020

Leuprorelin acetate depot in advanced prostatic cancer: a phase II multicentre trial

1 reference

12 December 2020

Bioavailability of leuprolide acetate following nasal and inhalation delivery to rats and healthy humans

1 reference

12 December 2020

Controlled release of LHRH agonist, leuprolide acetate, from microcapsules: serum drug level profiles and pharmacological effects in animals

1 reference

12 December 2020

Leuprolide versus diethylstilbestrol for metastatic prostate cancer

1 reference

12 December 2020

Serum concentration patterns of an LHRH agonist, gonadotrophins and sex steroids after subcutaneous, vaginal, rectal and nasal administration of the agonist to pregnant rats

1 reference

12 December 2020

Interim report of a large French multicentre study of efficacy and safety of 3.75 mg leuprorelin depot in metastatic prostatic cancer

1 reference

12 December 2020

Leuprorelin. A review of its pharmacology and therapeutic use in prostatic disorders

1 reference

12 December 2020

Evaluation of an implant that delivers leuprolide for 1 year for the palliative treatment of prostate cancer

1 reference

12 December 2020

One-month release injectable microcapsules of a luteinizing hormone-releasing hormone agonist (leuprolide acetate) for treating experimental endometriosis in rats

1 reference

12 December 2020

A randomized comparison of the clinical and hormonal effects of two GnRH agonists in patients with prostate cancer

1 reference

12 December 2020

Controlled-release of leuprolide acetate from polylactic acid or copoly(lactic/glycolic) acid microcapsules: influence of molecular weight and copolymer ratio of polymer

1 reference

12 December 2020

A phase II study of leuprolide in advanced/recurrent endometrial cancer

1 reference

12 December 2020

Synthetic analogs of luteinizing hormone releasing hormone (LH-RH) substituted in position 6 and 10.

1 reference

12 December 2020

Leuprorelin. A review of its pharmacology and therapeutic use in prostatic cancer, endometriosis and other sex hormone-related disorders

1 reference

12 December 2020

Gonadotropin-releasing hormone analog design. Structure-function studies toward the development of agonists and antagonists: rationale and perspective

1 reference

12 December 2020

In vivo release profiles of leuprolide acetate from microcapsules prepared with polylactic acids or copoly(lactic/glycolic) acids and in vivo degradation of these polymers

1 reference

12 December 2020

Successful transdermal administration of therapeutic doses of a polypeptide to normal human volunteers

1 reference

12 December 2020

A new technique to efficiently entrap leuprolide acetate into microcapsules of polylactic acid or copoly(lactic/glycolic) acid

1 reference

12 December 2020

Preparation of three-month depot injectable microspheres of leuprorelin acetate using biodegradable polymers

1 reference

12 December 2020

Percutaneous absorption enhancement of leuprolide

1 reference

12 December 2020

In vivo metabolism of tritiated LHRH by the whole kidney and individual tubules of rats

1 reference

12 December 2020

Extended release peptide delivery systems through the use of PLGA microsphere combinations

1 reference

12 December 2020

Sublingual absorption of leuprolide: comparison between human and animal models.

1 reference

12 December 2020

Safety and efficacy of an implantable leuprolide delivery system in patients with advanced prostate cancer.

1 reference

12 December 2020

Enhancing initial release of peptide from poly(d,l-lactide-co-glycolide) (PLGA) microspheres by addition of a porosigen and increasing drug load

1 reference

12 December 2020

Persistent suppression of the pituitary-gonadal system in female rats by three-month depot injectable microspheres of leuprorelin acetate

1 reference

12 December 2020

Desensitization of pituitary gonadotropin secretion by agonist-induced inactivation of voltage-sensitive calcium channels

1 reference

12 December 2020

Leuprolide acetate 22.5 mg 12-week depot formulation in the treatment of patients with advanced prostate cancer

1 reference

12 December 2020

Pharmaceutical aspects. Nasal and depot formulations of leuprolide

1 reference

12 December 2020

Gonadotropin-releasing hormone and its analogues: from laboratory to bedside

1 reference

12 December 2020

Efficacy and safety of leuprorelin acetate depot for prostate cancer. The German Leuprorelin Study Group

1 reference

12 December 2020

Sustained suppression of the pituitary-gonadal axis by leuprorelin three-month depot microspheres in rats and dogs

1 reference

12 December 2020

Pharmacokinetics, endocrine and antitumour effects of leuprolide depot (TAP-144-SR) in advanced prostatic cancer: a dose-response evaluation

1 reference

12 December 2020

An evaluation of pharmacokinetics and pharmacodynamics of leuprorelin acetate 3M-depot in patients with advanced and metastatic carcinoma of the prostate

1 reference

12 December 2020

Radioligand assay for gonadotropin-releasing hormone: relative potencies of agonists and antagonists

1 reference

12 December 2020

Hypophysial Responses to Continuous and Intermittent Delivery of Hypothalamic Gonadotropin-Releasing Hormone

1 reference

12 December 2020

Luteinizing Hormone Release and Gonadotropin-Releasing Hormone (GnRH) Receptor Internalization: Independent Actions of GnRH*

1 reference

12 December 2020

High-performance liquid chromatography followed by radioimmunoassay for the determination of a luteinizing hormone-releasing hormone analogue, leuprorelin, and its metabolite

1 reference

12 December 2020

Preparation of Biologically Active 125I LH-RH Suitable for Membrane-Binding Studies

1 reference

12 December 2020

Clinical study results of the new formulation leuprorelin acetate three-month depot for the treatment of advanced prostate carcinoma.

1 reference

12 December 2020

Sustained pharmacological activities in rats following single and repeated administration of once-a-month injectable microspheres of leuprolide acetate

1 reference

12 December 2020

Gonadotropin-releasing hormone and its analogues

1 reference

12 December 2020

Parameters affecting the efficacy of a sustained release polymeric implant of leuprolide

1 reference

12 December 2020

Formulation study of leuprorelin acetate to improve clinical performance

1 reference

12 December 2020

Hormonal treatment for prostate cancer.

1 reference

12 December 2020

Vaginal absorption of a potent luteinizing hormone-releasing hormone analogue (leuprolide) in rats II: mechanism of absorption enhancement with organic acids.

1 reference

12 December 2020

Clinical study of leuprolide depot formulation in the treatment of advanced prostate cancer. The Leuprolide Study Group

1 reference

12 December 2020

Hydrophobic ion pair formation between leuprolide and sodium oleate for sustained release from biodegradable polymeric microspheres

1 reference

12 December 2020

Discovery of a novel, potent, and orally active nonpeptide antagonist of the human luteinizing hormone-releasing hormone (LHRH) receptor

1 reference

12 December 2020

Biodegradable microspheres in drug delivery

1 reference

12 December 2020

Leuprorelin three-month depot in the treatment of advanced and metastatic prostate cancer: long-term follow-up results

1 reference

12 December 2020

Single-dose pharmacokinetics of leuprolide in humans following intravenous and subcutaneous administration

1 reference

12 December 2020

Pharmacokinetics of once-a-month injectable microspheres of leuprolide acetate

1 reference

12 December 2020

Leuprolide acetate depot and hormonal add-back in endometriosis: a 12-month study. Lupron Add-Back Study Group

1 reference

12 December 2020

A pilot study of intermittent androgen deprivation in advanced prostate cancer

1 reference

12 December 2020

Human pharmacokinetic and pharmacodynamic profiles of leuprorelin acetate depot in prostatic cancer patients

1 reference

12 December 2020

Sustained suppression of pituitary-gonadal axis with an injectable, in situ forming implant of leuprolide acetate

1 reference

12 December 2020

The sustained release of LH X RH agonist from LH X RH agonist-polymer composite in patients with prostatic cancer

1 reference

12 December 2020

Leuprolide acetate (30-mg depot every four months) in the treatment of advanced prostate cancer

1 reference

12 December 2020

A radioimmunoassay for a highly active luteinizing hormone-releasing hormone analogue and relation between the serum level of the analogue and that of gonadotropin

1 reference

12 December 2020

Pharmacokinetics of gonadotropin-releasing hormone and its analogs

1 reference

12 December 2020

Comparison of LH-RH analogue 1-month depot and 3-month depot by their hormone levels and pharmacokinetic profile in patients with advanced prostate cancer

1 reference

12 December 2020

10.2165/00003088-200241070-00003

Identifiers

DOI

1 reference

Dimensions Publication ID

31 July 2017

1015159249

0 references

1 reference